JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
